Yabao Pharmaceutical Group (600351.SS) Earnings Analysis
Yabao Pharmaceutical Group (600351.SS) has no confirmed upcoming earnings date. Trailing P/E 14.52.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 600351.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 600351.SS. This page updates as the calendar is published.
600351.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-06-30 | 0.09323 CNY | n/a | n/a | n/a |
| 2025-05-16 | 0.01077 CNY | n/a | n/a | n/a |
| 2024-09-28 | 0.07661 CNY | n/a | n/a | n/a |
600351.SS valuation and analyst view
| Trailing P/E | 14.52 |
|---|---|
| Trailing EPS | 0.46146 CNY |
| Price / book | 1.60 |
| Dividend yield | 5.31% |
| Market cap | 4.54B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Yabao Pharmaceutical Group (600351.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 600351.SS. This page updates as the calendar is published.
Did 600351.SS beat earnings last quarter?
Consensus estimate data was not available for 600351.SS's 2025-06-30 report.
What is 600351.SS's current P/E ratio and EPS?
600351.SS trades at a trailing P/E of 14.52 on trailing EPS of 0.4614614415285828 CNY.
What do analysts rate 600351.SS?
600351.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.